Special Episode: COVID-19 Vaccine - Trials and Tribulations

Special Episode: COVID-19 Vaccine - Trials and Tribulations

COVID-19 vaccines are navigating through the last stage of clinical trials, but hurdles still lie ahead for efficacy, distribution and FDA approval.

Episoder(1509)

Mike Wilson: Time to Leave the Pack Behind?

Mike Wilson: Time to Leave the Pack Behind?

Investors have become infatuated with the S&P 500, but a rotation to new leadership suggests a look toward stocks that have been off the radar.

19 Jan 20213min

Special Episode: Rates and FX Markets Eye the U.S. Policy Path

Special Episode: Rates and FX Markets Eye the U.S. Policy Path

As Congress and a new administration ponder new stimulus to navigate the pandemic, what will 2021 look like for FX and government bond markets?

15 Jan 202110min

Andrew Sheets: Rates and Inflation - Moving for the Right Reasons?

Andrew Sheets: Rates and Inflation - Moving for the Right Reasons?

Rising yields and inflation can create anxiety for investors, but the impact depends on why they’re rising. Chief Cross-Asset Strategist Andrew Sheets explains.

14 Jan 20212min

Adam Virgadamo: 5 Equities Investment Themes for 2021

Adam Virgadamo: 5 Equities Investment Themes for 2021

As vaccines continue to roll out and the world eyes a return to normal, several key themes are emerging that could shape investment returns.

13 Jan 20213min

Reza Moghadam: High Noon at the ECB Corral

Reza Moghadam: High Noon at the ECB Corral

Does a robust recovery in 2021 spell the end of European Central Bank action? One inconvenient fact may stand in the way: the lackluster rise in inflation.

12 Jan 20214min

Mike Wilson: So… What Isn’t Priced-In?

Mike Wilson: So… What Isn’t Priced-In?

Although 2021 is likely to be a better year economically, asset markets may not repeat the remarkable run of the past 9 months. So where should investors look?

11 Jan 20214min

Special Episode: Are the Clouds Clearing for European Equities?

Special Episode: Are the Clouds Clearing for European Equities?

Why a reflationary backdrop in 2021 could provide a boost to Europe’s cyclical value stocks. A look at the year ahead with Graham Secker, Head of the European and UK Equity Strategy Team.

8 Jan 202110min

Andrew Sheets: Three Implications of the “Blue Wave”

Andrew Sheets: Three Implications of the “Blue Wave”

Chief Cross-Asset Strategist Andrew Sheets explains why a Democrat sweep of Congress and the White House suggests more reflation and rotation in portfolios.

7 Jan 20213min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
kommentarer-fra-aftenposten
rss-borsmorgen-okonominyhetene
lydartikler-fra-aftenposten
finansredaksjonen
rss-vass-knepp-show
livet-pa-veien-med-jan-erik-larssen
tid-er-penger-en-podcast-med-peter-warren
pengepodden-2
okonomiamatorene
morgenkaffen-med-finansavisen
utbytte
stormkast-med-valebrokk-stordalen
rss-sunn-okonomi
rss-rettssikkerhet-bak-fasaden-pa-rettsstaten-norge-en-podcast-av-sonia-loinsworth-og-foreningen-rettssikkerhet-for-alle
lederpodden
arcticpodden